Text Size

Effectiveness of Aspirin in Compare With Heparin Plus Aspirin in Recurrent Pregnancy Loss Treatment

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Yazd Medical University
ClinicalTrials.gov Identifier:
NCT01542411
First received: February 25, 2012
Last updated: March 1, 2012
Last verified: February 2012
History of Changes
  Purpose

This study evaluated the effect of anticoagulant treatment on the live-birth rate in women with a history of at least two continuous unexplained miscarriages or thrombophilia. It also compared two methods of treatment with aspirin and aspirin plus heparin.


Condition
Recurrent Pregnancy Loss

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective

Resource links provided by NLM:

MedlinePlus related topics: Blood Thinners
U.S. FDA Resources

Further study details as provided by Yazd Medical University:

Enrollment: 520
Study Start Date: April 2008
Groups/Cohorts
recurrent pregnancy loss
thrombophilia, aspirin
heparin

  Eligibility

Ages Eligible for Study:   19 Years to 35 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

This project evaluated 520 women with unexplained recurrent miscarriage for four years. They had referred to recurrent abortion clinic of Yazd Reproductive sciences institute. Women with unexplained recurrent miscarriage included in this study

Criteria

Inclusion Criteria:

  • unexplained recurrent miscarriage,
  • women had previous venous or arterial thromboembolism or who were heterozygous or homozygous for mutations for FV Leiden G1691A, prothrombin gene G20210A (FII G20210A), and methyltetrahydrofolate reductase C677T (MTHFR C677T)

Exclusion Criteria:

  • abnormal karyotypes of both partners,
  • uterine and cervical anatomical disorders on pelvic ultrasonography or hysteroscopy,
  • abnormal ovaries and abnormal endocrine tests.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01542411

Locations
Iran, Islamic Republic of
Research and Clinical Centre for Infertility
Yazd, Iran, Islamic Republic of
Sponsors and Collaborators
Yazd Medical University
Investigators
Principal Investigator: Tahere Jahaninejad, MSC Yazd Shahid Sadoughi Medical Sciences University and Health Services, Yazd, Iran
  More Information

No publications provided

Responsible Party: Yazd Medical University
ClinicalTrials.gov Identifier: NCT01542411     History of Changes
Other Study ID Numbers: 2362
Study First Received: February 25, 2012
Last Updated: March 1, 2012
Health Authority: Iran: Ethics Committee

Additional relevant MeSH terms:
Aspirin
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
 Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents
Hematologic Agents
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics
Central Nervous System Agents

ClinicalTrials.gov processed this record on June 18, 2013